| FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER, Alexandr POPRACH and Jindrich FINEK. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers. BASEL: MDPI, 2019, vol. 11, No 12, p. 1-13. ISSN 2072-6694. Available from: https://dx.doi.org/10.3390/cancers11121856. |
Other formats:
BibTeX
LaTeX
RIS
@article{1623236,
author = {Fiala, Ondrej and Ostasov, Pavel and Sorejs, Ondrej and Liska, Vaclav and Büchler, Tomáš and Poprach, Alexandr and Finek, Jindrich},
article_location = {BASEL},
article_number = {12},
doi = {http://dx.doi.org/10.3390/cancers11121856},
keywords = {colorectal cancer; bevacizumab; beta-blocker; outcome; hypertension},
language = {eng},
issn = {2072-6694},
journal = {Cancers},
title = {Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients},
url = {http://dx.doi.org/10.3390/cancers11121856},
volume = {11},
year = {2019}
}
TY - JOUR
ID - 1623236
AU - Fiala, Ondrej - Ostasov, Pavel - Sorejs, Ondrej - Liska, Vaclav - Büchler, Tomáš - Poprach, Alexandr - Finek, Jindrich
PY - 2019
TI - Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients
JF - Cancers
VL - 11
IS - 12
SP - 1-13
EP - 1-13
PB - MDPI
SN - 20726694
KW - colorectal cancer
KW - bevacizumab
KW - beta-blocker
KW - outcome
KW - hypertension
UR - http://dx.doi.org/10.3390/cancers11121856
L2 - http://dx.doi.org/10.3390/cancers11121856
N2 - Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10-13.61) months and 26.8 (95% CI 22.2-32.2) months compared with 8.30 (95% CI 7.80-9.57) and 21.0 (95% CI 17.8-23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606-0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560-0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy.
ER -
FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER, Alexandr POPRACH and Jindrich FINEK. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. \textit{Cancers}. BASEL: MDPI, 2019, vol.~11, No~12, p.~1-13. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers11121856.
|
